リウマチ治療学の世界市場

リウマチ治療学の世界市場は2030年までに607億米ドルに達する見込み

2023年に489億米ドルと推定されたリウマチ治療学の世界市場は、2023～2030年の分析期間においてCAGR 3.1%で成長し、2030年には607億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである疾患修飾性抗リウマチ薬（DMARDs）は、CAGR 3.1%を記録し、分析期間終了時には513億米ドルに達すると予測されます。非ステロイド性抗炎症薬（NSAIDs）セグメントは、今後7年間のCAGRが3.6%と予測されています。

米国市場は132億米ドル、中国はCAGR 5％で成長すると予測

米国のリウマチ治療学市場は、2023年には132億米ドルになると推定されます。世界第2位の経済大国である中国は、2023年から2030年までの分析期間においてCAGR 5%で推移し、2030年までに120億米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2023年から2030年にかけてそれぞれ1.9%と2.7%の成長が予測されています。欧州では、ドイツがCAGR約2.3%で成長すると予測されています。オーストラリア、インド、韓国などの国々が牽引するアジア太平洋の市場は、2030年までに76億米ドルに達すると予測されます。

2024 年の魅力的な新しいレポート機能のご紹介

インフルエンサーのエンゲージメント統計へのフルアクセス

デジタルアーカイブと「MarketGlass」調査プラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつ協調的に解き放つことができます。当社の最先端のツールは、市場参入企業のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。レポート内の数字、統計、市場に関する説明は、この分野の専門家や影響力のある人々によって共有された、完全にキュレートされた洞察に基づいています。

リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。

企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス

1年間の無料レポート更新

主要プレーヤーの世界市場シェアを含む競合カバレッジ

複数の地域にまたがるプレーヤーの市場プレゼンス分析（好調/活発/ニッチ/マイナー）

専門家/インフルエンサーのインタビュー、ポッドキャスト、プレス発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇によって引き起こされる地政学的、経済的不安定性が、2024年の激動の情勢を作り出すと思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、敏捷性と戦略的先見性をもって投資判断を行うことが、生き残るために重要であることに変わりはないです。

調査対象企業の例（全46件）

• AbbVie, Inc.
• Amgen, Inc.
• Bristol-Myers Squibb Company
• Genentech, Inc.
• Janssen Biotech, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Rheumatology Therapeutics Market to Reach $60.7 Billion by 2030

The global market for Rheumatology Therapeutics estimated at US$48.9 Billion in the year 2023, is expected to reach US$60.7 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$51.3 Billion by the end of the analysis period. Growth in the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment is estimated at 3.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $13.2 Billion, While China is Forecast to Grow at 5% CAGR

The Rheumatology Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12 Billion by the year 2030 trailing a CAGR of 5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 2.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.6 Billion by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 46 Featured) -

• AbbVie, Inc.
• Amgen, Inc.
• Bristol-Myers Squibb Company
• Genentech, Inc.
• Janssen Biotech, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Rheumatology Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Uric Acid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Psoriatic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 30: World 16-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 33: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 36: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 37: World Rheumatology Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Osteoarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Osteoarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: World 16-Year Perspective for Osteoarthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• JAPAN
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Japan 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• CHINA
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: China 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: China 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: China 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• EUROPE
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Europe 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• FRANCE
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: France 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: France 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: France 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• GERMANY
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Germany 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Germany 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Germany 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Italy 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Italy 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Italy 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: UK 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: UK 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: UK 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Spain 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Spain 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Spain 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Russia 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Russia 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Russia 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Rest of Europe 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Rest of Europe 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Rest of Europe 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Rheumatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
• AUSTRALIA
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Australia 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Australia 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Australia 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• INDIA
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: India 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: India 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: India 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: South Korea 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: South Korea 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: South Korea 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Rheumatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Latin America 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Latin America 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Argentina 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Argentina 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Argentina 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Brazil 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Brazil 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Brazil 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Mexico 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Mexico 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Mexico 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Rest of Latin America 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Rest of Latin America 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Rest of Latin America 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Rheumatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Middle East 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Middle East 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Iran 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Iran 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Iran 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Israel 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Israel 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Israel 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: Saudi Arabia 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Saudi Arabia 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Saudi Arabia 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: UAE 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: UAE 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: UAE 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Rest of Middle East 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Rest of Middle East 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Rest of Middle East 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030
• AFRICA
  • Rheumatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 313: Africa 16-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Uric Acid Drugs, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 316: Africa 16-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Osteoarthritis, Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2014, 2024 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 319: Africa 16-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online for the Years 2014, 2024 & 2030

IV. COMPETITION